How does 0ACK's PE Ratio compare to its peers?

0ACK is expensive based on its Price-To-Earnings Ratio (40.7x) compared to the peer average (26x).

How does 0ACK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0ACK is expensive based on its Price-To-Earnings Ratio (40.7x) compared to the European Pharmaceuticals industry average (21.3x).

What is 0ACK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0ACK's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 0ACK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 0ACK's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Dottikon ES Holding (LSE:0ACK) - Stock Price, News & Analysis

0ACK Stock Overview

Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries worldwide. More details

0ACK fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 14.55% per year

Risk Analysis

No risks detected for 0ACK from our risk checks.

Dottikon ES Holding AG Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

GSK

LSE:GSK

UK£54.8b

Animalcare Group

AIM:ANCR

UK£148.5m

AstraZeneca

LSE:AZN

UK£162.4b

Price History & Performance

Summary of all time highs, changes and price drops for Dottikon ES Holding
Historical stock prices
Current Share Price	CHF 238.50
52 Week High	CHF 270.00
52 Week Low	CHF 205.00
Beta	1.13
11 Month Change	-4.41%
3 Month Change	-9.49%
1 Year Change	7.61%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	196.98%

Recent updates

Shareholder Returns

	0ACK	GB Pharmaceuticals	GB Market
7D	1.5%	-2.3%	0.8%
1Y	7.6%	-2.7%	6.6%

Return vs Industry: 0ACK exceeded the UK Pharmaceuticals industry which returned -2.7% over the past year.

Return vs Market: 0ACK matched the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0ACK's price volatile compared to industry and market?
0ACK volatility
0ACK Average Weekly Movement	3.3%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0ACK has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0ACK's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1913	726	Markus Blocher	dottikon.com

Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries worldwide. The company’s chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks. It also offers Dottisol, an isosorbide dimethyl ether for application as a solubility enhancer in cosmetic, pharma, and agro products, as well as a performance additive in various industries.

Dottikon ES Holding AG Fundamentals Summary

How do Dottikon ES Holding's earnings and revenue compare to its market cap?
0ACK fundamental statistics
Market cap	CHF 3.15b
Earnings (TTM)	CHF 80.63m
Revenue (TTM)	CHF 332.98m

40.7x

P/E Ratio

9.9x

P/S Ratio

Is 0ACK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0ACK income statement (TTM)
Revenue	CHF 332.98m
Cost of Revenue	CHF 121.22m
Gross Profit	CHF 211.76m
Other Expenses	CHF 131.13m
Earnings	CHF 80.63m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Nov 29, 2024

Earnings per share (EPS)	5.84
Gross Margin	63.59%
Net Profit Margin	24.21%
Debt/Equity Ratio	11.3%

How did 0ACK perform over the long term?

See historical performance and comparison

Dottikon ES Holding LSE:0ACK Stock Report